retatrutide triple agonist gip glp-1 glucagon receptor Sweet Temptation, bitter Truth: Diabetes in the Research Spotlight Retatrutide, a GIP, GLP-1 and

The Role of Market Competition in GLP-1 Pricing The most powerful driver of the weight loss drug price drop 2025 is the head-to-head battle between the two pharmaceutical giants, Novo Nordisk (Wegovy) and Eli Lilly (Zepbound)

Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

There are five known subtypes of Y receptors, namely, Y1R, Y2R, Y4R, Y5R, and Y6R

Sixty-three percent of the participants lost at least five percent of their body weight and about 33 percent lost at least 10 percent of their body weight

In recent years, weight-loss drugs have become a common addition to diet and exercise routines